Transferase Other Than Ribonuclease (2.) Patents (Class 435/193)
  • Patent number: 10017769
    Abstract: The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and c) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 10, 2018
    Assignee: INSTITUT PASTEUR
    Inventors: Philippe Despres, Sylvie Paulous, Elodie Crublet
  • Patent number: 10011839
    Abstract: The disclosure relates to a metabolic transistor in microbes such as bacteria and yeast where a competitive pathway is introduced to compete with a product pathway for available carbon so as to control the carbon flux in the microbe.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 3, 2018
    Assignee: William Marsh Rice University
    Inventors: Ka-Yiu San, George N. Bennett, Hui Wu
  • Patent number: 9951356
    Abstract: Modification of metabolic pathways includes genetically engineering at least one enzyme involved in elongating 2-ketoacids during leucine biosynthesis, and preferably at least isopropylmalate dehydrogenase or synthase (LeuB or LeuA in E. coli), to include at least such non-native enzyme, enzyme complex, or combination thereof to convert 2-ketobutyrate or 2-ketoisovalerate to a C7-C11 2-ketoacid, wherein the production of such is at a higher efficiency than if a purely native pathway is followed. The C7-C11 2-ketoacid may then be converted, via a native or genetically engineered thiamin dependent decarboxylase, to form a C6-C10 aldehyde having one less carbon than the C7-C11 2-ketoacid being converted. In some embodiments the C6-C10 aldehyde may then be converted via additional native or genetically engineered enzymes to form other C6-C10 products, including alcohols, carboxylic acids, and alkanes.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: April 24, 2018
    Assignee: Dow Global Technologies LLC
    Inventors: Paresh C. Sanghani, Brandon A. Rodriguez, Christopher C. Stowers, Amudhan Venkateswaran
  • Patent number: 9944963
    Abstract: The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 17, 2018
    Assignee: Codexis, Inc.
    Inventors: Christopher K. Savile, Emily Mundorff, Jeffrey C. Moore, Paul N. Devine, Jacob M. Janey
  • Patent number: 9944965
    Abstract: The present invention relates to methods for production of 2?Fucosyllactose by a microbial system comprising a ?-1,2 fucosyltransferase (FucT2) polynucleotide and a Guanosine 5?-diphospho-?-L-fucose (GDP-L-fucose) synthesis pathway using lactose as a substrate. Furthermore, the present invention relates to compositions comprising the microbial system.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 17, 2018
    Assignees: The Board of Trustees of the University of Illinois, Seoul National University R&DB Foundation
    Inventors: Won-Heong Lee, Panchalee Pathanibul, Josh Quarterman, Michael J. Miller, Yong-Su Jin, Jin-Ho Seo
  • Patent number: 9896696
    Abstract: Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and/or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cpf1 or Csm1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 20, 2018
    Assignee: Benson Hill Biosystems, Inc.
    Inventors: Matthew Begemann, Benjamin Neil Gray
  • Patent number: 9868971
    Abstract: Disclosed are methods and kits for controlling the length of overhangs at the ends of double stranded DNA based on a competitive inhibition. Further provided are ligase-independent methods for joining the two ends of DNA strands using the same. The present methods efficiently control the overhangs of ds DNA. This user-controlled overhangs supply a tool for efficient ligation in a ligase independent way and can be advantageously used in DNA recombinant technology such as cloning gene or DNA fragments of interest or PCR products.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: January 16, 2018
    Assignee: ENZYNOMICS CO. LTD.
    Inventors: Yong Keol Shin, Yunil Suh, Min Young Lee, Ah Rong Jeong
  • Patent number: 9856291
    Abstract: A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: January 2, 2018
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Chin-Kai Chuang, Yu-Hsyu Su, Tai-Yun Lin
  • Patent number: 9856302
    Abstract: An antimicrobial peptide which is a derivative of the peptide P-113. The amino acid sequence of the antimicrobial peptide is SEQ ID NO: 4 or SEQ ID NO: 5, in which the C-terminus is or is not modified with a NH2.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: January 2, 2018
    Assignee: GENERAL BIOLOGICALS CORPORATION
    Inventors: Wen-Chi Cheng, Ming-Sun Liu, Frank Lin, Chung-Yu Lan, Guan-Yu Lin, Hsueh-Fen Chen
  • Patent number: 9850470
    Abstract: Disclosed is a novel polyene-specific glycosyltransferase derived from Pseudonocardia autotrophica. The glycosyltransferase includes an amino acid sequence of SEQ ID NO: 1 and a gene encoding the glycosyltransferase. The glycosyltransferase is produced by a method which includes the steps of: culturing transgenic recombinant microorganisms; and isolating glycosyltransferase from the cultured recombinant microorganisms.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: December 26, 2017
    Assignee: INHA-INDUSTRY PARTNERSHIP INSTITUTE
    Inventors: Eung Soo Kim, Mi Jin Lee, Hye Jin Kim
  • Patent number: 9827287
    Abstract: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: November 28, 2017
    Assignee: BIOMARCK PHARMACEUTICALS, LTD.
    Inventor: Indu Parikh
  • Patent number: 9764018
    Abstract: The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: September 19, 2017
    Assignee: GLYCOVAXYN AG
    Inventors: Michael Wacker, Charles Waechter
  • Patent number: 9719121
    Abstract: Reaction solutions are disclosed herein comprising water, incompletely refined sucrose, and a glucosyltransferase enzyme that synthesizes insoluble poly alpha-1,3-glucan having at least 50% alpha-1,3 glycosidic linkages and a weight average degree of polymerization (DPw) of at least 100. The yield of poly alpha-1,3-glucan by a reaction solution herein is at least 7% of the weight of sucrose that was converted in the reaction solution. Further disclosed are methods of producing poly alpha-1,3-glucan using incompletely refined sucrose, and poly alpha-1,3-glucan produced by these methods.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 1, 2017
    Assignee: EI DU PONT DE NEMOURS AND COMPANY
    Inventors: Dean M Fake, Susan Marie Hennessey, Brian D Mather, Jennifer S Ovental, Wayne Atkinson, Tyler D Pritchett, Negash Adugna
  • Patent number: 9688954
    Abstract: The present invention relates to the enzymatic synthesis of oligosaccharides, particularly, sialylated oligosaccharides comprising the carbohydrate moeities of the gangliosides GM3, GD3, and GT3.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: June 27, 2017
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventor: Eric Samain
  • Patent number: 9683016
    Abstract: PSF 1-derived peptides and pharmaceutical compositions of the peptides are described for immunotherapy of cancer patients. The peptides and pharmaceutical compositions containing these peptides induce a CTL response for treating or preventing cancer.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 20, 2017
    Assignees: GENESTEM CO., LTD., OSAKA URBAN INDUSTRY PROMOTION CENTER
    Inventors: Hidekazu Tanaka, Motofumi Iguchi, Mari Yokoyama
  • Patent number: 9670500
    Abstract: This disclosure provides transgenic plants having enhanced traits such as increased yield, increased nitrogen use efficiency and enhanced drought tolerance; propagules, progeny and field crops of such transgenic plants; and methods of making and using such transgenic plants. This disclosure also provides methods of producing hybrid seed from such transgenic plants, growing such seed and selecting progeny plants with enhanced traits. Also disclosed are transgenic plants with altered phenotypes which are useful for screening and selecting transgenic events for the desired enhanced trait.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: June 6, 2017
    Assignee: Monsanto Technology LLC
    Inventor: Mark Scott Abad
  • Patent number: 9657045
    Abstract: A process for enabling the production of a particulate composition containing crystalline trehalose dihydrate is provided. Including allowing an ?-glycosyltrehalose-forming enzyme to act on liquefied starch derived from a microorganism of the genus Arthrobacter and a trehalose-releasing enzyme derived from a microorganism of the genus Arthrobacter along with a starch debranching enzyme and a cyclomaltodextrin glucanotransferase; allowing glucoamylase to act on the resulting mixture to obtain a saccharide solution containing ?,?-trehalose; precipitating crystalline ?,?-trehalose dihydrate from the above saccharide solution; collecting the precipitated crystalline ?,?-trehalose dihydrate by a centrifuge; and ageing and drying the collected crystals. Cyclomaltodextrin glucanotransferase derived from a microorganism of the genus Paenibacillus or a mutant enzyme thereof is used to increase the ?,?-trehalose content in the saccharide solution to over 86.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 23, 2017
    Assignee: HAYASHIBARA CO., LTD.
    Inventors: Takashi Shibuya, Seisuke Izawa
  • Patent number: 9657322
    Abstract: The invention relates to the field of poly-and oligosaccharides and their nutritional effects. In particular, it relates to the application of ?-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (?1?6) glucosidic linkages and one or more consecutive (?1?4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (?1?4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (?1?4) glucosidic linkages and making new (?1?4) and (?1?6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: May 23, 2017
    Assignee: RIJKSUNIVERSITEIT GRONINGEN
    Inventors: Lubbert Dijkhuizen, Marc Jos Elise Cornelis van der Maarel, Johannis Paulus Kamerling, Reinder Johannes Leemhuis, Slavko Kralj, Justyna Malgorzata Dobruchowska
  • Patent number: 9657110
    Abstract: The present invention provides a polypeptides capable of modulating tissue transglutaminase-induced cell behavior wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a tissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of SEQ ID NO: 1, The invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: May 23, 2017
    Assignee: ASTON UNIVERSITY
    Inventors: Russell Collighan, Martin Griffin, Kamila Pytel, Zhuo Wang
  • Patent number: 9631029
    Abstract: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognize and bind an epitope comprised in the spacer domain of ADAMTS-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: April 25, 2017
    Assignee: ROTTAPHARM BIOTECH S.R.L.
    Inventors: Riccardo Chiusaroli, Michela Visintin, Gianfranco Caselli, Lucio Claudio Rovati
  • Patent number: 9631224
    Abstract: To provide a method for simply measuring ethanolamine phosphate in a sample, and a reagent, kit, program and the like useful in the method. A measurement method of ethanolamine phosphate includes a first step of adding an enzyme, which can catalyze a reaction that forms acetaldehyde from ethanolamine phosphate, to a sample, and conducting a first enzymatic reaction to form acetaldehyde, phosphoric acid and ammonia; and a second step of quantifying at least one of the resultant acetaldehyde, phosphoric acid and ammonia to determine an amount of the ethanolamine phosphate in the measurement sample.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 25, 2017
    Assignee: HUMAN METABOLOME TECHNOLOGIES, INC.
    Inventors: Takushi Ohga, Yoshiaki Ohashi
  • Patent number: 9585380
    Abstract: The invention provides an isolated nucleic acid having a sequence encoding a spermidine/spermine acetyltransferase (“SSAT”), wherein translation of an mRNA comprising the encoded SSAT has increased basal translation and increased stimulated translation, compared to a wild-type mRNA encoding SSAT. Methods of use for the nucleic acid are also provided. Methods and compositions are also provided for reducing ischemia-reperfusion injury in organs or tissue for transplantation.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 7, 2017
    Assignee: TEMPLE UNIVERSITY—Of The Commonwealth System of Higher Education
    Inventors: Salim Merali, Oscar Mauricio Perez Leal, Magid Abou-Gharbia, Wayne E. Childers
  • Patent number: 9550982
    Abstract: The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 24, 2017
    Assignee: Codexis, Inc.
    Inventors: Christopher K. Savile, Emily Mundorff, Jeffrey C. Moore, Paul N. Devine, Jacob M. Janey
  • Patent number: 9505797
    Abstract: The present invention relates to targeted conversion of alpha-hydroxyalkylated residues in biomolecules in the presence of a directing methyltransferase, namely to targeted removal of the alpha-hydroxyalkyl moieties to give unmodified residues, or targeted derivatization of the alpha-hydroxyalkyl groups by covalent coupling of non-cofactor compounds represented by formula HQ-LX, wherein X represents a functional group or a reporter group attached via a linker moiety L, and QH is selected from HS—, HSe—, HO—H2N—, HN3 or HCN in the presence of a directing methyltransferase. Further development of the method of targeted conversion comprises methods for targeted labeling a biomolecule and method for detecting hydroxymethylated target sites in a biomolecule according to the present invention.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: November 29, 2016
    Assignee: Vilnius University
    Inventors: Saulius Klimasauskas, Zita Liutkeviciute, Edita Kriukiene
  • Patent number: 9452225
    Abstract: The invention relates to a GLP-1 prodrug of the general formula I: R1-(NHXaa1)-Xaa2-(OHis)-(GLP-1 peptide) (Formula I), wherein GLP-1 peptide is GLP-1(8-37) (SEQ ID NO: 1) or an analog thereof having a maximum of nine amino acid changes as compared to GLP-1(8-37), R1 is lower alkyl, (NHXaa1) is an amino acid, Xaa2 is an amino acid, and (OHis) is a radical of imidazole-lactic acid; or a pharmaceutically acceptable salt, amide, or ester of the prodrug. The invention also relates to specific GLP-1 parent drugs of the general formula II: (HOHis)-(GLP-1 peptide) (Formula II), as well as specific intermediate products.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 27, 2016
    Assignee: Novo Nordisk A/S
    Inventor: Jens C. Norrild
  • Patent number: 9447444
    Abstract: The disclosure relates to a nucleic acid molecule isolated from a Papaver somniferum cultivar that produces the opiate alkaloid noscapine which comprises 10 genes involved in the biosynthesis of opiate alkaloids.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 20, 2016
    Assignee: Sun Pharmaceutical Industries (Australia) Pty Ltd
    Inventors: Thilo Winzer, Ian Alexander Graham, Tracy Carol Walker
  • Patent number: 9422346
    Abstract: The present invention provides a polynucleotide having a function of regulating a content of a plant metabolite, a polypeptide having a function of regulating a content of a plant metabolite, a vector containing the polynucleotide or a part of the polynucleotide, and a transformed plant produced by using the vector, and a method for producing the transformed plant, and according to the above polynucleotide, polypeptide, vector, transformed plant and method, a novel gene regulating a content of a plant metabolite and use of the novel gene.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: August 23, 2016
    Assignee: JAPAN TOBACCO INC.
    Inventors: Soichiro Noguchi, Shoichi Suzuki, Masao Arai, Kaori Hamano
  • Patent number: 9399764
    Abstract: The present disclosure relates to recombinant proteins having N-acetylglucosaminyltransferase activity. The present disclosure further relates to methods for producing complex N-glycans including the steps of providing host cells containing such recombinant proteins and culturing the host cells such that the recombinant proteins are expressed.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: July 26, 2016
    Assignees: Novartis International Pharmaceutical, Ltd., Glykos Finland Oy
    Inventors: Jari Natunen, Anne Kanerva, Jukka Hiltunen, Markku Saloheimo, Heli Viskari, Anne Huuskonen
  • Patent number: 9382584
    Abstract: The invention provides improved methods for sequencing nucleic acids, e.g., for medical applications and biomedical research. The disclosed methods can be applied to rapid personalized medicine, genetic diagnosis, pathogen identification, and sequencing species genomes.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 5, 2016
    Assignee: The Regents of the University of California
    Inventor: Xiaohua Huang
  • Patent number: 9315835
    Abstract: The present invention provides novel lysophospholipid acyltransferases. The object of the present invention is attained by the nucleotide sequences of SEQ ID NOs: 1 and 6 and the amino acid sequences of SEQ ID NOs: 2 and 7 of the present invention.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: April 19, 2016
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventor: Misa Ochiai
  • Patent number: 9295629
    Abstract: A WNT-derived peptide and use thereof are described. WNT-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT protein, and has much higher stability and skin penetration potency than natural-occurring WNT protein. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: March 29, 2016
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 9273101
    Abstract: Functionalized self-assembling peptides suitable for obtaining hydrogels for use in a wide range of applications in the biomedical field, such as for the development of biomaterials for regenerative medicine and basic science research are described.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: March 1, 2016
    Assignee: Nanomed3D S.R.L.
    Inventors: Fabrizio Gelain, Angelo Luigi Vescovi
  • Patent number: 9255132
    Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: February 9, 2016
    Assignee: Compugen Ltd.
    Inventors: Yossef Kliger, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
  • Patent number: 9248152
    Abstract: The present invention relates to human neural stem cells (NSCs) transfected with a vector comprising a polynucleotide encoding human choline acetyltransferase (ChAT) and thereby stably expressing the human ChAT, a composition for treating Alzheimer disease or for improving a cognitive disorder comprising the human NSCs expressing a human ChAT. The present human NSCs genetically modified to express human ChAT, when transplanted into the brain of the animal AD model, successfully integrated into the host tissues and differentiated into the normal neuronal cells or glial cells. The instant genetically modified human NSCs stably express ChAT in the brain tissue of AD animal and thereby restore the acetylcholine level, and learning and memory function comparable to normal animal. The present genetically modified human NSCs expressing ChAT can be used for the treatment of AD as well as cognitive disorders due to other brain diseases and aging.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: February 2, 2016
    Assignee: CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Yun-Bae Kim, Seung Up Kim
  • Patent number: 9243269
    Abstract: The present disclosure provides for an expression system for the production of blue pigment indigoidine. The system comprises a heterologous host cell, a DNA sequence encoding a Sc-IndB protein, and a DNA sequence encoding a Sc-IndC protein. The system may be configured for the co-expression of the Sc-IndB and Sc-IndC. DNA sequences encoding the Sc-IndB and Sc-IndC may be provided on at least one vector. Alternatively, the DNA sequences encoding the Sc-IndB and Sc-IndC may optionally be integrated into the genome of the heterologous host genome. The expression system may further comprise a sfp gene or a PPTase.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: January 26, 2016
    Assignee: Utah State University
    Inventor: Jixun Zhan
  • Patent number: 9226947
    Abstract: A method for treating a microbial infection or an abscessed tissue in a subject includes administering to the subject an effective amount of a metal ion chelator. In some embodiments, the metal ion chelator can be a protein, such as a calprotectin heterodimer. In some embodiments, the metal ion chelator is a calprotectin heterodimer including an S100A8 polypeptide and an S100A9 polypeptide.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: January 5, 2016
    Assignee: Vanderbilt University
    Inventors: Eric P. Skaar, Brian Corbin
  • Patent number: 9217141
    Abstract: Disclosed is a transglutaminase having excellent stability. Also disclosed is a process for producing the transglutaminase. Specifically disclosed is a stabilized transglutaminase, which has such a structure in which a pro-sequence peptide of transglutaminase is bound to a mature transglutaminase. Also specifically disclosed is a process for producing stabilized transglutaminase, which includes the steps of: culturing a microorganism capable of producing transglutaminase under the conditions where transglutaminase can be produced; and separating and collecting matured transglutaminase having a pro-sequence peptide bound thereto from a culture medium.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 22, 2015
    Assignee: Amano Enzyme Inc.
    Inventors: Masamichi Okada, Yoshiaki Kurono, Hitoshi Amano, Shotaro Yamaguchi
  • Patent number: 9200311
    Abstract: The present invention provides methods and compositions for performing illuminated reactions, particularly sequencing reactions, while mitigating and/or preventing photodamage to reactants that can result from prolonged illumination. In particular, the invention provides methods and compositions for incorporating photoprotective agents into conjugates comprising reporter molecules and nucleoside polyphosphates.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: December 1, 2015
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Geoffrey Otto, Gene Shen, Xiangxu Kong, Robin Emig
  • Patent number: 9187544
    Abstract: Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators, are described. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: November 17, 2015
    Assignee: The Johns Hopkins University
    Inventors: Aleksander S. Popel, Emmanouil D. Karagiannis
  • Patent number: 9150893
    Abstract: Described herein are microorganisms that produce methionine and related products from endogenous genes in a transsulfuration pathway, as well as from exogenous genes providing a direct sulfhydrylation pathway. Novel genes that are useful for methionine and SAMe production are disclosed.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 6, 2015
    Assignee: CJ Cheiljedang Corporation
    Inventors: Brian Brazeau, Jin-Sook Chang, Kwang Myung Cho, Young Wook Cho, Mervyn Desouza, Holly J. Jessen, So-Young Kim, Wei Niu, Fernando A. Sanchez-Riera, Yong-Uk Shin, Hyewon Um
  • Patent number: 9127324
    Abstract: Disclosed is an O-phosphoserine sulfhydrylase (OPSS) mutant which has a Mycobacterium smegmatis-derived amino acid sequence corresponding to that of SEQ ID NO: 1 which is devoid of three to seven C-terminal amino acid residues. Also, a nucleic acid molecule encoding the OPSS mutant, an expression vector carrying the nucleic acid molecule, and a transformant transformed with the expression vector are disclosed. In addition, a method is provided for producing cysteine in which O-phospho-L-serine (OPS) is reacted with a sulfide in the presence of the OPSS mutant. The OPSS mutant has improved enzymatic activity and can be applied to the environmentally friendly production of L-cysteine through a simple enzymatic conversion reaction.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: September 8, 2015
    Assignee: CJ Cheildjedang Corporation
    Inventors: Soo An Shin, Jin Sook Chang, Hye Won Um, Jae Hyun Jo, Byeong Cheol Song, Kyoung Min Lee
  • Patent number: 9127288
    Abstract: The present invention relates to methods of producing lipids. In particular, the present invention relates to methods of increasing the level of one or more non-polar lipids and/or the total non-polar lipid content in a transgenic organism or part thereof. In one particular embodiment, the present invention relates to the use of an acyltransferase, for example, a monoacylglycerol acyltransferase (MGAT) to increase the level of one or more non-polar lipids and/or the total non-polar lipid content in plants, plant seed and/or leaves, algae and fungi.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: September 8, 2015
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: James Robertson Petrie, Thomas Vanhercke, Pushkar Shrestha, Oing Liu, Surinder Pal Singh
  • Patent number: 9051576
    Abstract: A recombinant yeast of the genus Komagataella which has been transformed with a galactose promoter is provided. The yeast is preferably Komagataella phaffii, and the promoter is preferably a S. cerevisiae GAL1 or GAL10 promoter. Vectors and methods for producing recombinant polypeptides are also provided.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: June 9, 2015
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventor: Bhupendra Vallabh Kara
  • Patent number: 9045797
    Abstract: Disclosed is a method of amplifying a polynucleotide, comprising: (a) mixing primers for amplifying the polynucleotide, a polymerase, nucleotide substrates and a template polynucleotide, and (b) amplifying the polynucleotide by polymerase reaction, wherein the polymerase has an amino acid sequence consisting of SEQ ID NO:1 or an amino acid sequence with at least 85% sequence identity to SEQ ID NO:1, and an amino acid residue corresponding to, or at position 651 of the amino acid sequence has been replaced with glutamic acid.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: June 2, 2015
    Assignee: ARKRAY, Inc.
    Inventors: Toshiya Hosomi, Mitsuharu Hirai
  • Publication number: 20150147783
    Abstract: The present invention relates to an isolated mutant eubacterium comprising at least one mutation resulting in a substitution of at least one amino acid in the beta-subunit of the RNA-polymerase encoded for by the rpoB-gene providing an altered production of a product of interest when said production of a product of interest is compared to the production of the same product in an isogenic wild type strain grown at identical conditions, wherein the substitution of at least one amino acid occurs at any of positions 469, 478, 482, 485, or 487 of SEQ ID NO:2, or at the equivalent positions in any eubacterial RNA-polymerase beta-subunit family member. Another aspect of the invention relates to a process for producing at least one product of interest in a mutant eubacterium and to a use of the mutant eubacterium according to the invention for producing at least one product of interest.
    Type: Application
    Filed: February 9, 2015
    Publication date: May 28, 2015
    Inventors: Steen Troels Joergensen, Jens Toenne Andersen, Niels Banke, Preben Nielsen
  • Publication number: 20150147330
    Abstract: Described herein is the identification of a panel of high affinity monoclonal antibodies that bind GPC3. The disclosed antibodies recognize native GPC3 on the surface of cancer cells, as well as soluble GPC3. The highest affinity antibody (YP7) was further characterized and shown to be highly sensitive in that it was capable of detecting cancer cells with low expression of GPC3. YP7 also exhibited significant HCC tumor growth inhibition in vivo. Immunotoxins comprising the antibodies disclosed herein fused to PE38 exhibited very high binding affinity for GPC3-expressing cells and significantly inhibited GPC3-expressing cancer cell growth. Thus, the high-affinity monoclonal antibodies disclosed herein can be used for the diagnosis and treatment of GPC3-expressing cancers.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 28, 2015
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventors: Mitchell Ho, Yen T. Phung, Wei Gao, Yifan Zhang
  • Publication number: 20150147780
    Abstract: Disclosed herein are embodiments for a novel method of producing an organic compound, including harvesting at least one organic compound from an organism or cell line genetically engineered with a gene for at least one proton-pump protein.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Eugene Dinescu, Vincent Dinescu
  • Patent number: 9040286
    Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: May 26, 2015
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Leonard I. Zon, Craig Ceol, Yariv J. Houvras
  • Publication number: 20150140605
    Abstract: The invention includes a selective method of modifying the N-terminus of a protein using an aminoacyl tRNA transferase. In certain embodiments, the method comprises contacting a solution of the protein or peptide with a transferase and a derivative of a molecule, whereby the N-terminus of the protein or peptide is derivatized with the molecule.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 21, 2015
    Inventor: E. James Petersson
  • Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent